Considerations for cancer immunotherapy biomarker research during COVID-19.
作者信息
Carlisle Jennifer W, Jansen Caroline S, Bilen Mehmet Asim, Kissick Haydn
机构信息
Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
出版信息
Endocr Relat Cancer. 2020 Sep;27(9):C1-C8. doi: 10.1530/ERC-20-0187.
Abstract
摘要
相似文献
1
Considerations for cancer immunotherapy biomarker research during COVID-19.2019年冠状病毒病期间癌症免疫治疗生物标志物研究的考量因素
Endocr Relat Cancer. 2020 Sep;27(9):C1-C8. doi: 10.1530/ERC-20-0187.
2
Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.曾接触过免疫检查点抑制剂的癌症患者感染2019冠状病毒病（COVID-19）的临床结局
Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.
3
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.免疫肿瘤学见解：癌症免疫治疗学会关于COVID-19患者使用白细胞介素-6靶向疗法的声明
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2020-000878.
4
Systemically comparing host immunity between survived and deceased COVID-19 patients.系统比较新冠病毒肺炎幸存者与死亡患者之间的宿主免疫力。
Cell Mol Immunol. 2020 Aug;17(8):875-877. doi: 10.1038/s41423-020-0483-y. Epub 2020 Jun 15.
5
SARS-CoV-2: a time for clear and immediate action.严重急性呼吸综合征冠状病毒2：是采取明确且立即行动的时候了。
Lancet Infect Dis. 2020 May;20(5):531-532. doi: 10.1016/S1473-3099(20)30250-4. Epub 2020 Mar 31.
6
Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.SARS-CoV-2 特异性抗体分泌细胞的扩增和住院 COVID-19 患者中中和抗体的产生。
J Immunol. 2020 Nov 1;205(9):2437-2446. doi: 10.4049/jimmunol.2000717. Epub 2020 Sep 2.
7
Possible causes for decreased susceptibility of children to coronavirus.儿童对冠状病毒易感性降低的可能原因。
Pediatr Res. 2020 Sep;88(3):342. doi: 10.1038/s41390-020-0892-8. Epub 2020 Apr 8.
8
Immunological features of coronavirus disease 2019 in patients with cancer.2019 年冠状病毒病患者的免疫学特征。
Eur J Cancer. 2020 Nov;139:70-80. doi: 10.1016/j.ejca.2020.08.013. Epub 2020 Sep 7.
9
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.2019年冠状病毒病（COVID-19）与抗风湿药物
Rheumatol Int. 2020 May;40(5):825-826. doi: 10.1007/s00296-020-04570-z. Epub 2020 Mar 30.
10
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.迫切需要开展针对新型冠状病毒肺炎的抗肿瘤坏死因子疗法试验。
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
本文引用的文献
1
Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.中性粒细胞与淋巴细胞比值可预测 2019 冠状病毒病重症患者的早期病情。
J Transl Med. 2020 May 20;18(1):206. doi: 10.1186/s12967-020-02374-0.
2
The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.白细胞介素-6 在监测 2019 年冠状病毒病重症病例中的作用。
EMBO Mol Med. 2020 Jul 7;12(7):e12421. doi: 10.15252/emmm.202012421. Epub 2020 Jun 5.
3
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.癌症患者似乎更容易感染 SARS-CoV-2：COVID-19 爆发期间的一项多中心研究。
Cancer Discov. 2020 Jun;10(6):783-791. doi: 10.1158/2159-8290.CD-20-0422. Epub 2020 Apr 28.
5
Cytokine release syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子释放综合征
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.
6
Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19.进退维谷——新冠疫情时期的肿瘤学决策
N Engl J Med. 2020 Jun 11;382(24):2285-2287. doi: 10.1056/NEJMp2006588. Epub 2020 Apr 7.
7
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.COVID-19 感染癌症患者的临床特征：中国武汉三家医院的回顾性病例研究。
Ann Oncol. 2020 Jul;31(7):894-901. doi: 10.1016/j.annonc.2020.03.296. Epub 2020 Mar 26.
8
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
9
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
10
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
Zotero 插件